Back
Arcus Biosciences Quote, Financials, Valuation and Earnings

10 POWERFUL Patterns...
Click here to download your copy now
Sell
36
RCUS
Arcus Biosciences
Last Price:
16.34
Seasonality Move:
17.96%
7 Day Trial
ALL ACCESS PASS
$
7

Make The SMART Move and Get The Inflation Survival Plan!
So don't wait until it's too late, act now and secure your future TODAY!Arcus Biosciences Price Quote
$16.34
+0.38 (+2.38%)
(Updated: March 23, 2023 at 11:10 PM ET)
Arcus Biosciences Key Stats
Sell
36
Arcus Biosciences (RCUS)
is a Sell
Day range:
$15.93 - $16.82
52-week range:
$15.70 - $39.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
10.26
P/B ratio:
1.77%
Volume:
1M
Avg. volume:
1.1M
1-year change:
-53.73%
Market cap:
$1.2B
Revenue:
$112M
EPS:
$-3.72
How Much Does Arcus Biosciences Make?
-
How Much Are Arcus Biosciences's Sales Annually?
RCUS Revenues are $112M -
How Much Profit Does Arcus Biosciences's Make A Year?
RCUS net income is -$267M
Is Arcus Biosciences Growing As A Company?
-
What Is Arcus Biosciences's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.91% -
What Is Arcus Biosciences's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Arcus Biosciences Stock Price Performance
-
Did Arcus Biosciences Stock Go Up Last Month?
Arcus Biosciences share price went down by -16.4% last month -
Did RCUS's Share Price Rise Over The Last Year?
RCUS share price fell by -53.73% over the past 1 year
What Is Arcus Biosciences 52-Week High & Low?
-
What Is Arcus Biosciences’s 52-Week High Share Price?
Arcus Biosciences has traded as high as $39.75 over the past 52 weeks -
What Is Arcus Biosciences’s 52-Week Low Share Price?
Arcus Biosciences has traded as low as $15.70 over the past 52 weeks
Arcus Biosciences Price To Free Cash Flow
-
Is Arcus Biosciences Stock Overvalued?
Arcus Biosciences is trading at a price to free cash flow ratio of 2.70 -
Is Arcus Biosciences Stock Undervalued?
Arcus Biosciences EV to Free Cash Flow ratio is 0.37 -
What Is Arcus Biosciences’s Price Earnings Growth Ratio?
RCUS PEG ratio is 0.00 -
Is Arcus Biosciences Trading At A Premium To Earnings?
Arcus Biosciences EV to EBIT ratio is 0.00
Is It Risky To Buy Arcus Biosciences?
-
How Much Debt Does Arcus Biosciences Have?
Total long term debt quarterly is $0 -
How Much Cash Does Arcus Biosciences Have?
Cash and short term investments quarterly total is $1B -
What Is Arcus Biosciences’s Book Value Per Share?
Book value per share is 9.01
Is Arcus Biosciences Cash Flow Positive?
-
What Is RCUS Cash Flow From Operations?
Cash flow from operations (TTM) is $438M -
What Is Arcus Biosciences’s Cash Flow From Financing?
Cash flow from financing (TTM) is $33M -
What Is Arcus Biosciences’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$413M
Arcus Biosciences Return On Invested Capital
-
Is Management Doing A Good Job?
RCUS return on invested capital is -35.68% -
What Is Arcus Biosciences Return On Assets?
ROA measures how assets are converting to revenues and is -18.16% -
What Is RCUS Return On Equity?
ROE is a measure of profitability and is -35.68%
Arcus Biosciences Earnings Date & Stock Price
-
What Is Arcus Biosciences's Stock Price Today?
A single share of RCUS can be purchased today for 15.96 -
What Is Arcus Biosciences’s Stock Symbol?
Arcus Biosciences trades on the nyse under the ticker symbol: RCUS -
When Is Arcus Biosciences’s Next Earnings Date?
The next quarterly earnings date for Arcus Biosciences is scheduled on May 9, 2023 -
When Is RCUS's next ex-dividend date?
Arcus Biosciences's next ex-dividend date is March 24, 2023 -
How To Buy Arcus Biosciences Stock?
You can buy Arcus Biosciences shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Arcus Biosciences Competitors
-
Who Are Arcus Biosciences's Competitors?
Below is a list of companies who compete with Arcus Biosciences or are related in some way:
Arcus Biosciences Dividend Yield
Data Unavailable
Arcus Biosciences Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 8.37% |
Revenue: | -90.51% | 43.34% |
Analyst Recommendations
Buy Recommendations: | 9 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 43.25 |
Upside from Last Price: | 170.99% |